ClinicalTrials.gg
RecruitingNCT04736732IPCOUpdated Apr 17, 2026

Institut de Recherche Cliniques de Montreal (IRCM) Post-COVID-19 (IPCO) Research Clinic

An observational study in Covid19 and Long COVID, sponsored by Emilia Falcone, MD. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-17.

Primary conditionPost-Acute COVID-19 SyndromeRegistry: COVID-19ReclassifiedWhy we changed it
Registry
COVID-19 — the first condition term the registry derived for this study.
ClinicalTrials.gg
Post-Acute COVID-19 Syndrome
Why
  1. The study's listed conditions name Post-Acute COVID-19 Syndrome, a narrower term within COVID-19.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Emilia Falcone, MD · Observational

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
650
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada — 14 open to participants now, 17 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Canada.

Started
2021
with 4 others
Observational
7 of 40
3 open now
Primary completion
2027-05
later than 8 of 16 live
Registered
1st of 40
by date

Among the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, this one is one of 5 that started in 2021, is one of 7 observational ones, reaches primary completion later than 8 of the 16 other live ones, and was the 1st registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

14 of the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, or all of them as a file.
02

Study summary

While many COVID19 studies are focusing on the immediate biological impact of SARS-CoV2 infection, this multidisciplinary research clinic will inform the global community on its recovery phase across patient cohorts with different degrees of disease severity (asymptomatic, mild [non-hospitalized], moderate/severe [hospitalized]). The primary objectives are to: 1) evaluate the short- and long-term end-organ complications post-COVID-19 in relation to the severity of the acute COVID-19 infection and 2) establish a post-COVID-19 biobank. The secondary objective is to develop a model that can predict end-organ complications using epidemiological and clinical data. To complete the objectives, the study will follow 6 patient cohorts: Patients who had previous asymptomatic or mild COVID-19 (no need for oxygen), patients who had previous moderate/severe COVID-19 (patients who had an oxygen requirement; moderate=oxygen by nasal cannula; severe=oxygen by high flow nasal cannula, non-invasive positive pressure ventilation or intubation), patients who had COVID-19 but did not develop the post-COVID-19 condition, patients who have never had COVID-19, patients who had flu-like symptoms but did not have signs or symptoms related to the infection lasting beyond 4 weeks from the date of symptom-onset, and patients with flu-like symptoms and have signs or symptoms related to the infection lasting beyond 4 weeks from the date of symptom-onset. Patients will be recruited into these cohorts using a strategy that targets the following populations: patients that were hospitalized in centers across Montreal, patients already followed at the IRCM (non-COVID-19) clinic, essential workers, and members of the same household as patients already enrolled in the IPCO clinic research protocol. The IPCO clinic research protocol is the first in the province of Quebec to systematically follow patients post-COVID-19 for short- and long-term complications including end-organ damage while building an extensive biobank that can support future mechanistic research projects.

Read the detailed description

Primary Objectives:

  1. Evaluate the short- and long-term end-organ complications post-COVID-19 in relation to the severity of the acute COVID-19 infection.
  2. Establish a post-COVID-19 biobank.

Secondary Objectives:

Develop a model that may predict the development of end-organ complications.

Primary Endpoint:

The development of any end-organ complication that can plausibly be related to COVID-19.

Secondary Endpoints:

  1. Detection of any new abnormality on echocardiogram >4 weeks after COVID-19 symptom-onset or diagnosis.
  2. Detection of any new abnormality on pulmonary function testing (PFT) or any change in PFT compared to a pre- or post-COVID-19 baseline PFT.
  3. An increase in liver enzymes > 2X upper limit of normal that occurs post-COVID-19 and is not associated to any other process (e.g., cholestasis, drug toxicity, alcohol abuse, hepatitis A, B, C, D, E).
  4. Any change in pre-COVID-19 weight, waist circumference or body mass composition.
  5. Any change in HgA1C, lipid profile or thyroid stimulating hormone (TSH) from pre-COVID-19 baseline that begins or persists >4 weeks after COVID-19 symptom-onset or diagnosis.
  6. A positive fecal calprotectin or lactoferrin measurement occurring >4 weeks after COVID-19 symptom-onset or diagnosis.
  7. Any significant change in renal parameters (e.g., micro-albuminuria, serum creatinine, glomerular filtration rate [GFR]) detected >4 weeks after COVID-19 symptom-onset or diagnosis.
  8. Any change in physical activity and/or exercise tolerance as measured by actimeter reading or 6-minute walk test (6MWT) with ambulatory oximetry
  9. Any change in well-being as measured by our WHO Well-Being Questionnaire
  10. Any change in functional status as measured with the Post COVID-19 Functional Status Scale (PCFS)
  11. Any change in quality of life, as measured by the European Quality of Life 5 Dimensions (EQ-5D-5L) tool
  12. Any detection or exacerbation of post-exertional malaise (PEM)/post-exertional symptom exacerbation (PESE) using the DePaul Symptom Questionnaire - Post-exertional malaise (DSQ-PEM) short form and the FUNCAP27 questionnaire
  13. Any detection of new (i.e., not known to be present prior to COVID-19 infection) cardiac dysautonomia using the 10-minute standing test.

Methodology:

Participants will have up to 5 medical visits (depending on the time since diagnosis and group) over the course of 60 months. The data will be collected for clinical monitoring and biobanking purposes.

Medical visits include:

  • Clinical assessment
  • Epidemiological questionnaire
  • Well-being questionnaire
  • Physical exam (if indicated)
  • Vital signs
  • Measurement of waist circumference
  • Weight and height measurement
  • Impedance / evaluation of body mass composition
  • Actimeter reading
  • Pulmonary function test
  • Echocardiography
  • Electrocardiogram
  • Urine collection
  • Blood draw
  • Saliva collection
  • Sebum collection
  • Stool collection (optional)
  • Nasopharyngeal swab (optional)
03

Conditions studied

  • Covid19
  • Long COVID

Browse trials for

Keywords

  • Post-COVID-19 syndrome
  • COVID-19-related long-term complications
  • COVID-19 long haulers
  • Post-COVID-19 condition
  • Post-acute sequelae of COVID-19
  • Long COVID
04

In context

Post-Acute COVID-19 Syndrome Reclassified

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

This study's planned enrollment of 650 is above the median of 150 across 173 observational studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

This is the only study on the registry with Emilia Falcone, MD as lead sponsor.

Compared within Post-Acute COVID-19 Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is COVID-19. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

  • Adults who have had a positive diagnosis of COVID-19.
  • Adults who have tested negative for COVID-19
  • Adults with a history of acute flu-like illness

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any gender, ≥ 18 years old
  • Current resident of Quebec
  • Speaks English or French
  • Have a personal email (to which to send reminders and questionnaire by email )

AND

1 of the following criteria:

  • Individuals with at least one COVID-19 positive PCR test, serology or antibody/antigen test in the last 60 months at day of recruitment. In the absence of a positive COVID-19 test, individuals with symptoms consistent with COVID-19 while living with a person who had a confirmed positive PCR, serology or antibody/antigen COVID-19 test in the last 60 months at day of recruitment (epidemiologic link).

OR

  • Individuals who tested negative for COVID-19 while living with a household member who tested positive for COVID-19 or had a close contact with the viral infection in the context of their work, and never had any COVID-19 related symptoms (presumed COVID negative control group).

OR

  • Individuals who don't have any COVID-19 related symptoms actually, have never had tested positive, and have had at least one negative PCR, serology or antibody/antigen COVID-19 test (presumed COVID negative control group).

OR

  • Individuals with an undiagnosed viral infection in the last 60 months at day of recruitment and have persistent symptoms (or not) after the participant has recovered from a viral infection.

Exclusion criteria

Exclusion Criteria:

  • Any participant not deemed appropriate for enrollment according to the PI
  • Known pregnancy (female will not be automatically screened for pregnancy upon enrollment unless there is a possibility that they might be pregnant)
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
650 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Long COVID group

    Patients who had previous asymptomatic or mild COVID-19 and have signs or symptoms related to COVID-19 lasting beyond 4 weeks from the date of COVID-19 symptom-onset or diagnosis (mild=never required supplemental oxygen during the acute phase of the infection)

    Other: Medical follow-up

  • Long COVID-hospitalized group

    Patients who had previous moderate or severe COVID-19 and have signs or symptoms related to COVID-19 lasting beyond 4 weeks from the date of COVID-19 symptom-onset or diagnosis (moderate=required supplemental oxygen by nasal cannula during the acute phase of the infection; severe=required supplemental oxygen by either high-flow nasal cannula, non-invasive positive pressure ventilation or intubation

    Other: Medical follow-up

  • COVID-19 Recovered group

    Patients who had COVID-19 but did not have signs or symptoms related to COVID-19 lasting beyond 4 weeks from the date of COVID-19 symptom-onset or diagnosis

    Other: Medical follow-up

  • COVID-19 negative group

    Presumed COVID negative patients (i.e., either 1) patients who never had symptoms consistent with COVID-19 AND never tested positive for COVID-19 by molecular or rapid test.)

    Other: Medical follow-up

  • Recovered post-viral group

    Patients with a history of acute flu-like illness who do not continue to experience persistent signs or symptoms attributable to the infection for ≥4 weeks from symptom onset.. Eligible patients may have laboratory-confirmed viral infection other than COVID-19 or a suspected viral infection without laboratory confirmation. Patients with confirmed COVID-19 are excluded

    Other: Medical follow-up

  • Symptomatic post-viral group

    Patients with a history of acute flu-like illness who continue to experience persistent signs or symptoms attributable to the infection for ≥4 weeks from symptom onset. Eligible patients may have laboratory-confirmed viral infection other than COVID-19 or a suspected viral infection without laboratory confirmation. Patients with confirmed COVID-19 are excluded.

    Other: Medical follow-up

Interventions

  • OtherMedical follow-up

    Patients will be followed for medical evaluation and for biobanking of data and biological samples.

    Also known as: Sample collection

07

What researchers measure

Primary outcomes

  1. The development of any end-organ complication that can be plausibly related to COVID-19. The following end-organ systems will be evaluated: cardiovascular.

    The development of any cardiovascular complication that can be plausibly related to COVID-19 will be evaluated.

    Time frame: 5 years

  2. The development of any end-organ complication that can be plausibly related to COVID-19. The following end-organ systems will be evaluated: pulmonary.

    The development of any pulmonary complication that can be plausibly related to COVID-19 will be evaluated.

    Time frame: 5 years

  3. The development of any end-organ complication that can be plausibly related to COVID-19. The following end-organ systems will be evaluated: renal.

    The development of any renal complication that can be plausibly related to COVID-19 will be evaluated.

    Time frame: 5 years

  4. The development of any end-organ complication that can be plausibly related to COVID-19. The following end-organ systems will be evaluated: endocrine.

    The development of any endocrine complication that can be plausibly related to COVID-19 will be evaluated.

    Time frame: 5 years

  5. The development of any end-organ complication that can be plausibly related to COVID-19. The following end-organ systems will be evaluated: metabolic.

    The development of any metabolic complication that can be plausibly related to COVID-19 will be evaluated.

    Time frame: 5 years

  6. The development of any end-organ complication that can be plausibly related to COVID-19. The following end-organ systems will be evaluated: gastro-intestinal (GI).

    The development of any gastro-intestinal complication that can be plausibly related to COVID-19 will be evaluated.

    Time frame: 5 years

Secondary outcomes

  1. Detection of any new abnormality on echocardiogram >4 weeks after COVID-19 symptom-onset or diagnosis.

    Detection of any new abnormality on echocardiogram \>4 weeks after COVID-19 symptom-onset or diagnosis.

    Time frame: 5 years

  2. Detection of any new abnormality on pulmonary function testing (PFT) or any change in PFT compared to a pre- or post-COVID-19 baseline PFT

    Detection of any new abnormality on pulmonary function testing (PFT) or any change in PFT compared to a pre- or post-COVID-19 baseline PFT

    Time frame: 5 years

  3. An increase in liver enzymes > 2X upper limit of normal that occurs post-COVID-19 and is not associated to any other process (e.g., cholestasis, drug toxicity, alcohol abuse, hepatitis A, B, C, D, E).

    An increase in liver enzymes \> 2X upper limit of normal that occurs post-COVID-19 and is not associated to any other process (e.g., cholestasis, drug toxicity, alcohol abuse, hepatitis A, B, C, D, E).

    Time frame: 5 years

  4. Any change in pre-COVID-19 weight, waist circumference or body mass composition

    Any change in pre-COVID-19 weight, waist circumference or body mass composition

    Time frame: 5 years

  5. Any change in HgA1C, lipid profile or thyroid stimulating hormone (TSH) from pre-COVID-19 baseline that begins or persists >4 weeks after COVID-19 symptom-onset or diagnosis

    Any change in HgA1C, lipid profile or thyroid stimulating hormone (TSH) from pre-COVID-19 baseline that begins or persists \>4 weeks after COVID-19 symptom-onset or diagnosis

    Time frame: 5 years

  6. A positive fecal calprotectin or lactoferrin measurement occurring >4 weeks after COVID-19 symptom-onset or diagnosis

    A positive fecal calprotectin or lactoferrin measurement occurring \>4 weeks after COVID-19 symptom-onset or diagnosis

    Time frame: 5 years

  7. Any significant change in renal parameters (e.g., micro-albuminuria, serum creatinine, glomerular filtration rate [GFR]) detected >4 weeks after COVID-19 symptom-onset or diagnosis

    Any significant change in renal parameters (e.g., micro-albuminuria, serum creatinine, glomerular filtration rate \[GFR\]) detected \>4 weeks after COVID-19 symptom-onset or diagnosis

    Time frame: 5 years

  8. Any change in physical activity and/or exercise tolerance as measured by actimeter reading or 6-minute walk test (6MWT) with ambulatory oximetry

    Any change in physical activity and/or exercise tolerance as measured by actimeter reading or 6-minute walk test (6MWT) with ambulatory oximetry

    Time frame: 5 years

  9. Any change in well-being as measured by our WHO Well-Being Questionnaire

    Raw Score: Sum of 5 items (ranging from 0 = "At no time" to 5 = "All of the time"). Total Range: 0 to 25. Percentage Score: (raw score) X 4. Represents a scale of 0-100. Interpretation: 0-25: Low well-being, potential depression (further evaluation recommended). 26-50: Suboptimal well-being. 51-100: Good mental well-being.

    Time frame: 5 years

  10. Any change in functional status as measured with the Post COVID-19 Functional Status Scale (PCFS)

    No limitations = PCFS Score 0 Negligible limitations = PCFS Score 1 Slight limitations = PCFS Score 2 Moderate limitations = PCFS Score 3 Severe limitations = PCFS Score 4

    Time frame: 5 years

  11. Any change in quality of life, as measured by the European Quality of Life 5 Dimensions (EuroQol-5D) tool

    A unique health state is defined by combining one level from each of the five dimensions. Each of the five dimensions comprising theEQ-5D-5L descriptive system is divided into five levels of perceived problems: LEVEL 1: no problem LEVEL 2: slight problems LEVEL 3: moderate problems LEVEL 4: severe problems LEVEL 5: unable to/extreme problems A unique health state is defined by combining one level from each of the five dimensions. A total of 3125 possible health states is defined in this way. Each state is referred to by a 5-digit code. For example, working clockwise from the top of the diagram, state 12345 indicates no problems with mobility, slight problems with washing or dressing, moderate problems with doing usual activities, severe pain or discomfort and extreme anxiety or depression, while state 11111 indicates no problems on any of the five dimensions.

    Time frame: 5 years

  12. Any detection or exacerbation of post-exertional malaise (PEM)/post-exertional symptom exacerbation (PESE) using the DePaul Symptom Questionnaire - Post-exertional malaise (DSQ-PEM) short form questionnaire

    Scoring Step 1 Items 1-5: A frequency and severity score of 2, 2 on any items 1-5 is indicative of PEM. Range 0-4 Scoring Step 2 Items 7, 8: Either item 7 or 8 must have an answer of yes to indicate an ME and/or CFS dx. Item 9: A response of \>14 h is needed to indicate an ME and/or CFS dx. Items 6, 10: Neither item indicates an ME and/or CFS diagnosis, but provides a description of patient PEM for clinical evaluations

    Time frame: 5 years

  13. Any detection of new (i.e., not known to be present prior to COVID-19 infection) cardiac dysautonomia using the 10-minute standing test.

    Evaluation of any new cardiac dysautonomia using the 10-minute standing test.

    Time frame: 5 years

  14. Any detection or exacerbation of post-exertional malaise (PEM)/post-exertional symptom exacerbation (PESE) using the Questionnaire on functionnal capacity (FUNCAP27)

    Scored 0-6: 0: I cannot do this 1. My capacity will be severely reduced for at least three days 2. I can do little else on the same day and for one to two days afterwards 3. I can do little else on the same day 4. I must limit other activities on the same day 5. This rarely affects other activities 6. Unproblematic - does not affect other activities

    Time frame: 5 years

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • https://doi.org/10.21203/rs.3.rs-8876163/v1
  • https://doi.org/10.21203/rs.3.rs-8876425/v1

Individual participant data

Plan to share: Yes — Future collaborations will be possible with data from the biobank. All data will be anonymous and a committee will evaluate requests for access to the biobank. The principal investigator is responsible for the biobank.

Time frame: All material (original or derived) and data will be stored for as long as the biobank has a scientific interest for the community and the director can ensure its management.

Access criteria: Recognized researcher collaborating with PI.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for May 2027, 75 months after the start.

Of 97 non-industry observational studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 75 months is above that.

Counting every sponsor, half of 104 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2021
First posted
Feb 3, 2021
StartActual
Feb 1, 2021
Primary completionEst.
May 4, 2027
CompletionEst.
Nov 4, 2027
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04736732
Lead sponsor
Emilia Falcone, MD
Responsible party
Emilia Falcone, MD (Director, IRCM Post-COVID-19 Research Clinic, Institut de Recherches Cliniques de Montreal) — Sponsor-investigator
First posted
Feb 3, 2021
Start date
Feb 1, 2021
Primary completion
May 4, 2027 (estimated)
Completion
Nov 4, 2027 (estimated)
Last update
Apr 17, 2026

Study contacts

Emilia Liana Falcone, M.D., Ph.D.
Contact
Emilia.falcone@ircm.qc.ca
514-987-5610
Charlotte Du Sablon, M.Sc.
Contact
Charlotte.Dusablon@ircm.qc.ca
514-987-5581
Emilia Liana Falcone, M.D., Ph.D.
principal investigator · IRCM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion